Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125810243 | 12581024 | 3 | F | 20160628 | 20160819 | 20160721 | 20160823 | EXP | PHJP2016JP020517 | NOVARTIS | 89.00 | YR | F | Y | 0.00000 | 20160823 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125810243 | 12581024 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH2.5 (CM2), (CONTAIN 4.5 MG OF RIVASTIGMINE BASE), | 22083 | 1.9 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||
| 125810243 | 12581024 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH5 (CM2), (CONTAIN 9 MG OF RIVASTIGMINE BASE) | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||
| 125810243 | 12581024 | 3 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH7.5 (CM2), (CONTAIN 13.5 MG OF RIVASTIGMINE BASE) | 22083 | 6.9 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||
| 125810243 | 12581024 | 4 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | (PATCH10 (CM2), (CONTAIN 18 MG OF RIVASTIGMINEBASE) | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||||
| 125810243 | 12581024 | 5 | SS | STALEVO | CARBIDOPAENTACAPONELEVODOPA | 1 | Oral | 3 DF, QD (1 DF CARBIDOPA 10 MG/ ENTACAPONE 100 MG/LEVODOPA 100 MG) | 0 | 3 | DF | TABLET | QD | ||||||
| 125810243 | 12581024 | 6 | C | NEODOPASTON | CARBIDOPALEVODOPA | 1 | Unknown | 100 MG, TID | 0 | 100 | MG | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125810243 | 12581024 | 1 | Dementia Alzheimer's type |
| 125810243 | 12581024 | 5 | Parkinson's disease |
| 125810243 | 12581024 | 6 | Parkinson's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125810243 | 12581024 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125810243 | 12581024 | Blood pressure increased | |
| 125810243 | 12581024 | Lacunar infarction | |
| 125810243 | 12581024 | Snoring |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125810243 | 12581024 | 1 | 201412 | 0 | ||
| 125810243 | 12581024 | 4 | 201503 | 0 | ||
| 125810243 | 12581024 | 5 | 201606 | 0 | ||
| 125810243 | 12581024 | 6 | 201606 | 0 |